Insider buying last 90 days
No open-market insider purchases were filed for TWST in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every TWST insider filing, plotted on the chart in Gekko.Open TWST in Gekko
NASDAQ: TWST
Twist Bioscience (TWST) Stock Analysis & Forecast
Sep 28 close
$179.60−3.23 (−1.8%)
Gekko Brief
AI summaryTwist Bioscience shares have been driven this week by a mix of AI-linked enthusiasm and profit-taking debate. Leerink Partners raised its price target to $160 and pointed to the company as a beneficiary of Anthropic's expanding biology research, a call that coincided with a 16% single-day jump. Separately, commentary has questioned whether the stock's rise from $1.7 billion to $12 billion in market capitalization reflects multiple expansion and short covering rather than fundamental growth, while shares also touched a new 52-week high of $192 before retreating to $183. CEO Emily Leproust's routine sell-to-cover and 10b5-1 plan transactions were also disclosed.
The stock closed at $179.60, down 1.8% on the day, but remains well above both its 50-day ($127.99) and 200-day ($73.91) moving averages, with the 50-day above the 200-day. The GekkoIndex reads 43.6, placing TWST in the Distribution zone. Price sits 50.2% above Gekko Fair Value of $119.60, a gap the checklist flags as a headwind despite the supportive trend.
Over the next 20 trading days, the next earnings report is scheduled for 13 November, outside that window. Options activity shows 1 unusual signal in the last 30 days, with call premium of $492,200 and no put premium recorded. Seasonality over 5 years shows a -1.6% average for this stretch, positive in 2 of those years. The consensus among 8 analysts includes 5 buy, 2 hold and 1 sell ratings, with a consensus target of $109.58.
Written by AI and checked automatically against the figures on this page. Generated Sep 29, 2026 from the data above.
Twist Bioscience price vs fair value
Close $179.60200-day averageGekko Fair Value $119.60
Twist Bioscience quick facts
- Market cap
- $11.18B
- P/E ratio
- —
- Forward P/E
- —
- EPS, TTM
- −$2.59
- Revenue, TTM
- $431.8M
- Profit margin
- -31.7%
- Dividend yield
- —
- Beta
- 2.22
- Volume
- 2.20M avg 2.00M
- 1-year return
- +571.4%
- Typical daily move
- ±6.5%
- Typical 20-day move
- ±14.6%
- 50-day average
- $127.99
- 200-day average
- $73.91
- Next earnings
- Nov 13 before open
- Shares outstanding
- 66.30M
Twist Bioscience swing-trade checklist
Twist Bioscience scores 3 supportive, 0 mixed and 3 headwinds across the 6 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
3 supportive0 mixed3 headwinds
- Trendsupportive
Above 50 and 200-day
Close $179.60 is above the 50-day ($127.99) and 200-day ($73.91) averages, and the 50-day is above the 200-day.
See the chart - GekkoIndexheadwind
43.6, Distribution
Reading 43.6 is in the Distribution zone.
See the GekkoIndex - Fair valueheadwind
50.2% above
Price is 50.2% above Gekko Fair Value (more than 5% above).
See fair value - Smart moneysupportive
Leans bullish
Last 30 days: 1 unusual options signal.
See smart money - Earnings risksupportive
Reports in 45 days
Next report Nov 13, 2026, 45 days away — outside a typical 20-trading-day hold.
See earnings - Seasonalityheadwind
−1.6% on average
From this point in the calendar, the next 20 trading days averaged −1.6% over 5 years, rising in 2 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Twist Bioscience stock chart and price history
Twist Bioscience closed at $179.60 on Sep 28, 2026, +571.4% over the past year, inside a 52-week range of $23.30 to $187.87.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- +17.3%
- 3 months
- +82.6%
- 6 months
- +303.3%
- 1 year
- +571.4%
The full TWST chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open TWST in Gekko
Follow Twist Bioscience through every session
Put TWST on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track TWST in GekkoFree for 7 days. No credit card required.
About Twist Bioscience
Twist Bioscience makes synthetic DNA and related products for research and biotechnology customers. Its manufacturing approach writes artificial DNA strands directly onto silicon chips, and it is known for this chip-based synthesis method. From this platform it produces custom genes, tools for preparing genetic samples, antibody libraries used in drug research, and methods for storing digital data in DNA.
The company works with outside partners rather than only selling standalone products. It has collaborations with organizations such as Victorian Clinical Genetic Services, Vivlion GmbH, Kyowa Kirin Pharmaceutical Research, deepCDR Biologics AG, and Centogene N.V., aimed at developing sequencing technology. It also has a research partnership with Boehringer Ingelheim, supplying its antibody libraries so the two can search for and develop antibody-based therapies against a range of biological targets.
Twist Bioscience was founded in 2013 and is based in South San Francisco, California. Its shares are listed on the NASDAQ under the ticker TWST.
- Listed
- NASDAQ
- Sector
- Health technology
- Industry
- Biotechnology
- Website
- twistbioscience.com
Twist Bioscience GekkoIndex: the smart money zone
Twist Bioscience’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 43.6, in the Distribution zone, up 1.5 points over five sessions.
43.6Distribution
Up 1.5 points over five sessions.
Reading for Sep 28, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 29 | +4.8% | +15.9% | ||
| Accumulation | 204 | +1.2% | +6.7% | ||
| Neutral | 385 | +1.7% | +5.2% | ||
| Distribution (current zone) | 53 | +1.6% | +5.0% | ||
| Selling | 1 | Too few readings yet | |||
Average TWST share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Distribution readings averaged +1.2% over 20 days. Past behaviour doesn’t guarantee future results.
Distribution zone: Institutions potentially offloading. About the five zones →
See every daily GekkoIndex reading plotted over the TWST price, zone by zone.Track TWST in Gekko
Is Twist Bioscience stock overvalued? Gekko Fair Value
Twist Bioscience trades 50.2% above Gekko Fair Value of $119.60, so the shares are overvalued on Gekko’s estimate.
Gekko’s own estimate of what Twist Bioscience shares are worth, recalculated every trading day.
$119.60
Gekko Fair Value, Sep 26, 2026
50.2% Overvalued
Gekko Fair Value on every chart, with the gap to price updating daily.Open TWST in Gekko
Twist Bioscience insider and Congress trading
No open-market insider purchases were filed for Twist Bioscience, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in TWST were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for TWST, plotted on the chart in Gekko.Open TWST in Gekko
Buybacks
Twist Bioscience has been buying back its own shares.
- Bought back, quarter ended Jun 30, 2026
- $6K
- As a share of market cap
- 0.00%
- Trailing four quarters
- $18K
From company filings.
Unusual options activity last 30 days
1signal, 100% of the flagged premium in calls.
Latest: Bullish flow on Sep 19, $492K in unusual premium.
Hedge funds and billionaires quarter ended Jun 30
0of the funds Gekko tracks hold TWST.
0added0opened0trimmed1sold out
Every signal with its contract, strike and premium, and which funds are on each side.Unlock in Gekko
Twist Bioscience earnings: next date and track record
Twist Bioscience reports on Nov 13, 2026, before the open (45 days away), and beat the EPS estimate in 4 of its last 8 reports.
Next earnings report
Nov 13, 2026
Expected before the open, 45 days away
- EPS estimate
- −$0.44
- Revenue estimate
- $123.6M
4 of 8reports beat the EPS estimate
±10.8%average move across the report
3 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Aug 3, 2026 AI summary
- What they said
- Twist Bioscience reported fiscal 2026 Q3 results with record revenue of $118.4M, 23% YoY growth—their 14th consecutive quarter of growth. Management highlighted AI-enabled drug discovery as a major growth driver, substantial growth in DNA synthesis and protein solutions (therapeutics) and NGS applications, improving gross margin to 52.8%, and guidance to adjusted EBITDA breakeven in Q4. They emphasized platform differentiation, scaling capacity, enzyme development, MRD growth, and durable customer relationships. Management expressed confidence in sustained growth, raising Q4 guidance by $12M and expecting >20% full-year growth. The company plans ongoing investment in automation, digital capabilities, and capacity expansion for data characterization. Q&A focused on AI order visibility, conversion to revenue, adjusted EBITDA path, competition, product mix, and market dynamics. Overall tone was confidently optimistic with focus on execution and durable opportunities.
- Guidance
- Guidance provided: Q4 FY2026: nearly 25% growth quarter-over-quarter implied and adjusted EBITDA breakeven expected in Q4 FY2026. Full-year fiscal 2026 growth guidance >20%. Management plans to provide full-year guidance in November for fiscal 2027. No specific numerical guidance for FY2027, but management expects continued strong growth and triple-digit AI order growth in 2026 (and potentially again in 2027).
- Risks flagged
- Risks noted: general forward-looking statement disclaimers; dependence on customer adoption and timing of orders; potential supplier dependence for enzymes (management discussed plans to reduce reliance); competitive actions/discounting noted as a possible market dynamic (investor question) but management downplayed impact. No major new risks explicitly emphasized during the call.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 3, 2026 | −$0.56 est −$0.50 | $118.4M est $114.5M | +8.6% |
| May 4, 2026 | −$0.71 est −$0.48 | $110.7M est $107.6M | −6.1% |
| Feb 2, 2026 | −$0.50 est −$0.48 | $103.7M est $101.9M | +12.8% |
| Nov 14, 2025 | −$0.45 est −$0.50 | $99.01M est $97.40M | −11.5% |
| Aug 4, 2025 | −$0.47 est −$0.54 | $96.06M est $97.38M | −18.3% |
| May 5, 2025 | −$0.66 est −$0.56 | $92.79M est $95.39M | −16.5% |
| Feb 3, 2025 | −$0.53 est −$0.63 | $88.71M est $86.95M | −0.7% |
| Nov 18, 2024 | −$0.59 est −$0.70 | $84.71M est $82.71M | +12.0% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Twist Bioscience stock forecast and analyst price targets
Analysts’ average 12-month price target for Twist Bioscience is $109.58, −39.0% from the last close, from 8 firms rating the stock in the last 90 days.
$109.58consensus 12-month target, −39.0% from the last close
Now $179.60Avg $109.58
Low $45High $160
Each firm’s latest rating in the last 90 days: 8 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Sep 18 | BWS Financial | $45 | −74.9% |
| Sep 17 | Leerink Partners | $160 | −10.9% |
| Sep 9 | UBS | $144 | −19.8% |
| Aug 4 | Robert W. Baird | $115 | −36.0% |
| Aug 3 | Canaccord Genuity | $120 | −33.2% |
+5.0%average 20-day move after past Distribution readings
−1.6%average move over the next 20 trading days in the last 5 years
±6.5%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Twist Bioscience seasonality: the next 20 trading days
Over the next 20 trading days from Sep 29, Twist Bioscience averaged −1.6% across the last 5 years, rising in 2 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +0.5% | 2 of 5 |
| Next 10 trading days | −3.6% | 2 of 5 |
| Next 15 trading days | −0.3% | 3 of 5 |
| Next 20 trading days | −1.6% | 2 of 5 |
| Next 30 trading days | +0.9% | 2 of 5 |
For scale, TWST’s typical 20-trading-day move in either direction is about 14.6%.
Twist Bioscience market cap and key statistics
Twist Bioscience’s market cap is $11.18B and revenue of $431.8M over the last twelve months.
Valuation
- Market cap
- $11.18B
- EPS, TTM
- −$2.59
- Gekko Fair Value
- $119.60
Trading
- Volume
- 2.20M
- Avg volume, 20 days
- 2.00M
- 52-week high
- $187.87
- 52-week low
- $23.30
- Shares outstanding
- 66.30M
Financials
- Revenue, TTM
- $431.8M
- Profit margin
- -31.7%
- Return on equity
- -29.6%
- Quarterly earnings growth, YoY
- 0.0%
Risk and income
- Beta
- 2.22
- Typical daily move
- ±6.5%
- Typical 20-day move
- ±14.6%
Twist Bioscience stock news this week
Coverage of Twist Bioscience this week reads neutral: 5 positive, 10 neutral and 4 negative headlines.
- Twist Bioscience: Don't Confuse A Short Squeeze With An AI Revolution (NASDAQ:TWST)Seeking Alpha, Sep 28
- Twist Bioscience Corp (Derivatives) Price History and Historical DataCoinMarketCap, Sep 28
- Twist Bioscience Corporation (TWST) Stock Price, News, Quote & HistoryYahoo! Finance Canada, Sep 28
- Twist Bioscience CEO Emily Leproust sells $279,183 in stockInvesting.com, Sep 27
- Form 4 Twist Bioscience Corp For: 27 September By Investing.comInvesting.com Nigeria, Sep 27
- Twist Bioscience Stock Jumped 16% Thursday. Leerink Says Anthropic Made It Happen.TIKR.com, Sep 25
Twist Bioscience peers
Twist Bioscience’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| AMGNAmgen | Neutral | 24.4% below |
| GILDGilead Sciences | Neutral | 6.9% above |
| MRNAModerna | Neutral | 73.2% above |
| NTRANatera | Distribution | 25.1% above |
| IQVIQVIA | Neutral | 14.2% above |
| UTHRUnited Therapeutics | Accumulation | 23.6% below |
A peer links to its own page where one exists.
Twist Bioscience stock FAQ
What is Twist Bioscience’s market cap?
Twist Bioscience’s market cap is $11.18B at the Sep 28, 2026 close of $179.60, with 66.30M shares outstanding.
What is the Twist Bioscience stock forecast?
The consensus analyst 12-month price target for Twist Bioscience is $109.58, −39.0% from the last close. Of the 8 firms that rated the stock in the last 90 days, 5 rate it a buy, 2 a hold and 1 a sell. Gekko doesn’t publish price predictions of its own.
Is Twist Bioscience stock overvalued or undervalued?
On Gekko’s estimate Twist Bioscience is overvalued: the Sep 28, 2026 close of $179.60 is 50.2% above Gekko Fair Value of $119.60. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Twist Bioscience report earnings next?
Twist Bioscience is expected to report on Nov 13, 2026, before the market opens (45 days away). Analysts expect earnings of −$0.44 per share on revenue of $123.6M. Twist Bioscience beat the earnings estimate in 4 of its last 8 reports, moving 10.8% on average across the report.
What is Twist Bioscience’s 52-week high and low?
Twist Bioscience’s 52-week high is $187.87 and its 52-week low is $23.30; it closed at $179.60 on Sep 28, 2026, +571.4% over the past year.
Is Twist Bioscience stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 6 items with data read as supportive (trend, smart money and earnings risk) and 3 as headwinds (gekkoindex, fair value and seasonality). The checklist is a description of current data, not a recommendation.
Is there unusual options activity in Twist Bioscience?
Gekko flagged 1 unusual options signal in Twist Bioscience over the last 30 days, with $492K of flagged premium in calls and $0 in puts. The latest, bullish flow, was on Sep 19, 2026 with $492K in unusual premium. The signal-by-signal table is in Gekko.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Twist Bioscience the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,380 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.